GV has contributed to a $92m series B round for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.
Tenaya Therapeutics, a US-based developer of treatments for heart disease, completed a $92m series B round yesterday featuring GV, a corporate venturing subsidiary of internet and technology group Alphabet.
The round was led by healthcare investment firm Casdin Capital and included Column Group and a range of undisclosed new and existing shareholders.
Founded in 2016 to leverage Gladstone Institutes and University of Texas Southwestern Medical Center research, Tenaya is working on drugs that address the underlying causes of heart disease. Its…
